FFC#15/2015

Impact of anti-Staphylococcus aureus treatment on Pseudomonas aeruginosa-induced lung damage

FFC#15/2015

Impact of anti-Staphylococcus aureus treatment on Pseudomonas aeruginosa-induced lung damage

PRINCIPAL INVESTIGATOR

Daniela Maria Cirillo (Unità Batteri Patogeni Emergenti, Divisione di Immunologia, Trapianti e Malattie Infettive – Istituto Scientifico San Raffaele, Milano)

RESEARCHERS

6

CATEGORY

AREA 3 Bronchopulmonary infection

DURATION

2 years

GOAL

€ 70.000 €

RESULTS

Staphylococcus aureus (SA – Newman) and Pseudomonas aeruginosa (PA14) reference strains were used to establish chronic co-infection in C57Bl/6NCr mice. Different protocols of amoxicillin/clavulanate (AC) administration were tested in mice infected by SA. After SA infection and antibiotic treatment mice were infected by Pa. Mice were monitored for body weight, mortality and lungs were processed for bacterial count, inflammatory response and histological analysis.
Treatment with 200 mg/Kg of AC was effective in containing SA infection with a decrease of SA bacterial load and inflammatory response up to 26 days from infection. However, both infection and inflammation were not completely resolved in this model. The capacity of SA pre-infection to increase Pa colonization was not affected by anti-SA treatment in murine lungs. Histopathology revealed that the antibiotic did not resolve completely the lung damage that was worsen by the Pa infection able to increase leukocytes recruitment at both bronchial and parenchymal levels.

OTHER RESULTS

FFC #3/2024

Two molecules are effective in activating Heat Shock Proteins and enhancing the action of CFTR correctors with the F508del mutation in vitro.

FFC#5/2024

Some peptide nucleic acids (PNAs) re-sensitise Pseudomonas aeruginosa to the antibiotic meropenem in vitro and reduce its virulence.

FFC#1/2023

Tezacaftor, one of the components of Kaftrio, induces an accumulation of dihydroceramides both in vitro and in vivo in animal models